drugset
drugset / Trial / NCT05384691

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

NCT05384691 ↗

Phase 2 Recruiting 213 enrolled University of Leipzig Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS), that are non-transfusion dependent

Timeline

Start
2022-09-27
Primary completion
2026-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic 1.75 mg/kg Subcutaneous

Indications

anemia myelodysplastic syndrome